Effectiveness and Controversy of Convalescent Plasma Therapy for Coronavirus Disease 2019 Patients

Since the coronavirus disease 2019 (COVID-19) began to spread, it remains pandemic worldwide. The European Medicines Agency's human medicines committee and Food and Drug Administration have only granted a conditional marketing authorization for remdesivir to treat COVID-19. It is essential to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Zhanjun, Wu, Peipei, Qian, Qianqian, Zhou, Li, Du, Dandan, Ding, Mengxuan, Peng, Tao, Fang, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772051/
https://www.ncbi.nlm.nih.gov/pubmed/37521156
http://dx.doi.org/10.1097/ID9.0000000000000033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772051/
https://www.ncbi.nlm.nih.gov/pubmed/37521156
http://dx.doi.org/10.1097/ID9.0000000000000033

Ejemplares similares